Venture capital poured over $8 billion into longevity-focused biotechnology in 2025, making it one of the few sectors that saw consistent growth during the broader funding contraction. The bet being made is ambitious: that the diseases of aging are treatable, even reversible, and that whoever solves them will operate in a market worth trillions.
Longevity medicine encompasses a broad range of approaches: senolytics that clear out damaged cells, mTOR pathway interventions, epigenetic reprogramming, and more speculative technologies like partial cell reprogramming. What was science fiction a decade ago is now in human clinical trials.
The ethical dimensions are significant. If effective anti-aging treatments exist, who gets access? Concentrated lifespan advantage among the already-advantaged would compound inequality across generations in ways that are difficult to model and potentially impossible to reverse.
"The technology is moving faster than the ethics," said one bioethicist involved in advising a major EU regulatory body. "That's almost always a problem."